Comparison of Serum Contraceptive Hormone Levels Between Normal Weight and Obese Users of the NuvaRing®

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Pharmacokinetics
Interventions
DRUG

NuvaRing

Obese subjects (BMI 30-39.9) will receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.

DRUG

NuvaRing

Normal weight subjects will also receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.

Trial Locations (1)

10032

Division of Family Planning and Preventive Services, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Organon

INDUSTRY

lead

Columbia University

OTHER